Brought to you by 
AZ and Amgen jointly develop and sell five inflammation therapies
02 Oct 2020
Executive Summary
AstraZeneca PLC, its biologics arm MedImmune LLC, and Amgen Inc. have agreed to jointly develop and commercialize five of Amgen’s clinical-stage monoclonal antibodies: AMG139, AMG157, AMG181, AMG557, and brodalumab (AMG827).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ and Amgen jointly develop and sell five inflammation therapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice